News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
1,057 Results
Type
Article (58)
Company Profile (1)
Press Release (998)
Section
Business (181)
Deals (34)
Drug Development (160)
FDA (43)
Job Trends (16)
News (441)
Policy (51)
Tag
Academia (3)
Alliances (65)
Antibody-drug conjugate (ADC) (2)
Approvals (43)
Best Places to Work (11)
Biotechnology (1)
Cancer (17)
Career advice (1)
Cell therapy (1)
Clinical research (160)
Collaboration (5)
Data (14)
Diagnostics (1)
Drug pricing (1)
Earnings (69)
Events (103)
Executive appointments (1)
FDA (48)
Funding (3)
GLP-1 (1)
Government (4)
Healthcare (9)
Intellectual property (1)
IPO (11)
Job creations (4)
JPM (1)
Legal (1)
Manufacturing (2)
Medical device (32)
Medtech (32)
Mergers & acquisitions (28)
NextGen: Class of 2026 (7)
Non-profit (4)
Pancreatic cancer (11)
Patents (1)
Patient recruitment (1)
People (47)
Phase 1 (23)
Phase 2 (90)
Phase 3 (50)
Pipeline (12)
Policy (1)
Postmarket research (10)
Preclinical (13)
Real estate (2)
Regulatory (54)
Research institute (1)
Series B (2)
Startups (4)
Vaccines (3)
Venture capital (1)
Date
Last 30 days (6)
Last 365 days (61)
2026 (9)
2025 (58)
2024 (47)
2023 (67)
2022 (91)
2021 (45)
2020 (41)
2019 (44)
2018 (42)
2017 (64)
2016 (65)
2015 (72)
2014 (67)
2013 (64)
2012 (63)
2011 (52)
2010 (38)
Location
Asia (61)
Australia (8)
California (6)
Canada (1)
China (3)
Europe (82)
Florida (1)
Illinois (21)
India (1)
Massachusetts (22)
Nevada (1)
New Jersey (20)
New York (10)
North Carolina (1)
Northern California (2)
Pennsylvania (1)
South America (4)
Southern California (3)
Texas (38)
United States (85)
Wisconsin (2)
1,057 Results for "actuate therapeutics.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
January 22, 2026
·
7 min read
Press Releases
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
January 6, 2026
·
10 min read
Press Releases
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026
December 19, 2025
·
6 min read
Press Releases
Actuate Therapeutics Announces Proposed Public Offering of Common Stock
September 10, 2025
·
3 min read
Press Releases
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma
December 16, 2025
·
10 min read
Press Releases
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock
September 11, 2025
·
3 min read
Press Releases
Actuate Therapeutics Advances a New Era in Oncology with Potential Universal Backbone Therapy
August 26, 2025
·
10 min read
Press Releases
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026
January 13, 2026
·
9 min read
Press Releases
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
September 23, 2025
·
8 min read
Press Releases
Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
September 12, 2025
·
3 min read
1 of 106
Next
